Clinical trial
Study of the Effects of Mecamylamine and Varenicline in Schizophrenia
NCT00455650 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00455650 |
|---|---|
| Title | Study of the Effects of Mecamylamine and Varenicline in Schizophrenia |
| Official title | Cognitive Effects of Mecamylamine and Varenicline in Schizophrenia |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | National Alliance for Research on Schizophrenia and Depression The Bowman Family Foundation |
| Status | Completed |
| Study type | Interventional |
| Conditions | Cognition in Schizophrenia |
| Intervention type | Drug |
| Interventions | Mecamylamine, Varenicline, Placebo |
| Enrollment | 89 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 1, 2013 |
| Completion | Jan 1, 2013 |
| First posted | Apr 4, 2007 |
| Last update posted | Mar 28, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: